Skip to search formSkip to main contentSkip to account menu

DORAVIRINE

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
BACKGROUND Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2… 
2020
2020
Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus-1… 
2019
2019
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1… 
2018
2018
Abstract Background Doravirine (DOR) is a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI). In the phase 3 DRIVE… 
2018
2018
Over the past 30 years, antiretroviral drug regimens for treating HIV infection have become more effective, safer, and more… 
2018
2018
Abstract Background Doravirine is a novel, non-nucleoside reverse-transcriptase inhibitor (NNRTI) that has demonstrated efficacy… 
2016
2016
World Health Organization estimates that 34 million individuals globally are living with Human Immunodeficiency Virus (HIV… 
2015
2015
Weight-Adjusted LNG Concentrations Weight was a predictor of LNG concentrations (1kg increase in weight = 5pg/mL decrease in LNG… 
2014
2014
Currently there are 28 approved antiretroviral drugs in six mechanistic classes, and recommended first‐line regimens are highly…